Immunai (NY – US/IL)

https://www.immunai.com

Twitter: @Immunaitech

LinkedIn: https://www.linkedin.com/company/immunai

Immunai is on a mission to reprogram the immune system to advance personalized medicine to better detect, diagnose, and treat disease. The team is composed of genomics, machine learning, bioinformatics, immunology, and software engineering experts and is headquartered in New York City, with offices in San Francisco and Tel Aviv. The company has raised $80M in funding to-date from Viola Ventures, TLV Partners, Schusterman Family Office, Duquesne Family Office, Catalio Capital Management, and Dexcel Pharma. *

	Start	2018-12-01 established
	Group	Immunai (Group)
	Industry	BIOTECH
	Industry 2	AMICA™ database (Annotated Multi-omic Immune Cell Atlas)
	Person	Solomon, Noam (Immunai 202005 CEO + Co-Founder)
	Person 2	Cogdill, Alexandria (Immunai 202103– Director of Business Development before MD Anderson Cancer Center)

	Region	New York, NY
	Country	United States (USA)
	Street	180 Varick Street 6th Floor
	City	10014 New York, NY
		Address record changed: 2021-01-20

Basic data	Employees	n. a.

		* Document for ï¿½About Sectionï¿½: Immunai. (2/11/21). "Press Release: Immunai Raises $60M to Reprogram Immunity". New York, NY.

		Record changed: 2021-04-06

Picture [iito] Plain Stupid Simple 650x80px

More documents for Immunai (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]